Cypherpunk Technologies (CYPH) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The 2025 Annual Meeting will be held virtually on June 18, 2025, with voting available online, by phone, mail, or during the meeting.
Proxy materials are distributed electronically to reduce costs and environmental impact, with printed copies available upon request.
Stockholders of record as of April 30, 2025, are eligible to vote on three main proposals.
Forward-looking statements address clinical development, regulatory progress, and financial projections, subject to risks and uncertainties.
Voting matters and shareholder proposals
Stockholders will vote on electing three Class II directors for terms ending in 2028.
An advisory vote on executive compensation (Say-on-Pay) is included.
Ratification of EisnerAmper LLP as independent auditors for 2025 is proposed.
Board recommends voting “FOR” all proposals.
Board of directors and corporate governance
Board consists of ten members divided into three classes with staggered three-year terms.
Majority of directors are independent per Nasdaq rules; only the CEO and Chairman are not independent.
Board committees include audit, compensation, and nominating/governance, each with defined charters and independent chairs.
Board leadership is separated between CEO and Chairman, with a Lead Independent Director.
Directors are encouraged to attend annual meetings and participate in ongoing education.
Latest events from Cypherpunk Technologies
- Returned to profitability in 2025 with strong ZEC gains, new capital, and clinical progress.CYPH
Q4 202516 Mar 2026 - Phase 2 trials for DKN-01 in gastric and colorectal cancer near key data readouts and expansion.CYPH
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - Sirexatamab shows strong efficacy in GI cancer trials; FL-501 advances toward clinical studies.CYPH
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Sirexatamab improved response rates in CRC, especially in DKK1-high and VEGF-naive patients.CYPH
Study Result9 Jan 2026 - Shareholders approved key proposals including share increase, reverse split, and new equity plan.CYPH
AGM 202515 Dec 2025 - Stockholders to vote on key capital, governance, and compensation proposals; Board urges approval.CYPH
Proxy Filing2 Dec 2025 - Stockholders will vote on key capital structure changes and equity plans at a virtual meeting.CYPH
Proxy Filing2 Dec 2025 - Virtual annual meeting on June 18, 2025, with key votes on directors, pay, and auditor.CYPH
Proxy Filing2 Dec 2025 - Sirexatamab delivers higher response rates and PFS in key colorectal cancer subgroups.CYPH
Status Update24 Nov 2025